ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the ALX Oncology First Quarter twenty twenty six Financial Results Conference and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I will now turn the conference over to your host, Jason Letman, CEO. Please go ahead, sir. Thanks, everyone, and welcome to our Q1 twenty twenty six results. Really appreciate you all spending time with us this morning and are, looking forward to sharing these updates with you. On slide two, and before we start our presentation as housekeeping, here are our forward looking statements for your review. On slide three, here's the agenda and plan for today. We're gonna be providing an update on our key accomplishments in the first quarter of twenty twenty six. Most notably, we are very excited to share with you the dataset that was presented yesterday in Munich at ESMO Breast twenty twenty six from the analysis of our trial evaluating evaporcept and zanidatumab, which clearly showed again that c d 47 expression is a key predictive biomarker for increasing durable clinical response in heavily pretreated HER two positive patients. This further validates the results we saw with EVO and HER two positive gastric cancer from our ASPEN six trial. We are also very excited today to be joined by doctor Sarah Hervetz from the Fred Hutch Cancer Center at the University of Washington, who is a well recognized expert in metastatic breast cancer. She will be presenting the ESMO breast data in detail and also share her views on evobracept's significant potential within the current treatment paradigm for HER two positive metastatic breast cancer. Our CMO, Barb Quincke, will then recap our findings to dat...